These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37550891)

  • 1. Glucose-lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.
    Isaksen AA; Sandbaek A; Skriver MV; Bjerg L
    Diabetes Obes Metab; 2023 Nov; 25(11):3307-3316. PubMed ID: 37550891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guideline-level monitoring, biomarker levels and pharmacological treatment in migrants and native Danes with type 2 diabetes: Population-wide analyses.
    Isaksen AA; Sandbæk A; Skriver MV; Andersen GS; Bjerg L
    PLOS Glob Public Health; 2023; 3(10):e0001277. PubMed ID: 37851595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.
    Tang H; Shao H; Shaaban CE; Yang K; Brown J; Anton S; Wu Y; Bress A; Donahoo WT; DeKosky ST; Bian J; Guo J
    J Am Geriatr Soc; 2023 Jul; 71(7):2096-2106. PubMed ID: 36821780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial infarction in type 2 diabetes using sodium-glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptor agonists: proportional hazards analysis by deep neural network based machine learning.
    Yamada T; Iwasaki K; Maedera S; Ito K; Takeshima T; Noma H; Shojima N
    Curr Med Res Opin; 2020 Mar; 36(3):403-409. PubMed ID: 31855074
    [No Abstract]   [Full Text] [Related]  

  • 5. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of socioeconomic disadvantage and remoteness with receipt of type 2 diabetes medications in Australia: a nationwide registry study.
    Morton JI; Ilomӓki J; Magliano DJ; Shaw JE
    Diabetologia; 2021 Feb; 64(2):349-360. PubMed ID: 33078206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis.
    Jia S; Wang Z; Han R; Zhang Z; Li Y; Qin X; Zhao M; Xiang R; Yang J
    Acta Diabetol; 2021 Jan; 58(1):5-18. PubMed ID: 32514989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the use of glucose-lowering drugs: A Danish nationwide study.
    Pottegård A; Andersen JH; Søndergaard J; Thomsen RW; Vilsbøll T
    Diabetes Obes Metab; 2023 Apr; 25(4):1002-1010. PubMed ID: 36514856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta-analyses-driven approach.
    Brønden A; Christensen MB; Glintborg D; Snorgaard O; Kofoed-Enevoldsen A; Madsen GK; Toft K; Kristensen JK; Højlund K; Hansen TK; Søndergaard E; Hansen KB
    Diabet Med; 2023 Aug; 40(8):e15157. PubMed ID: 37249579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes.
    Yang JY; Moon AM; Kim H; Pate V; Barritt AS; Crowley MJ; Buse JB; Stürmer T; Alexopoulos AS
    J Diabetes Complications; 2020 Nov; 34(11):107706. PubMed ID: 32843283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
    Lajara R
    Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020.
    Johansson KS; Bülow C; Jimenez-Solem E; Petersen TS; Christensen MB
    Lancet Healthy Longev; 2023 Dec; 4(12):e685-e692. PubMed ID: 38042161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Migration and health: exploring the role of migrant status through register-based studies.
    Nørredam M
    Dan Med J; 2015 Apr; 62(4):B5068. PubMed ID: 25872539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.
    Chen WH; Li Y; Yang L; Allen JM; Shao H; Donahoo WT; Billelo L; Hu X; Shenkman EA; Bian J; Smith SM; Guo J
    PLoS One; 2024; 19(1):e0297208. PubMed ID: 38285682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study.
    Rathmann W; Bongaerts B; Kostev K
    Diabetes Obes Metab; 2016 Aug; 18(8):840-3. PubMed ID: 27062643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
    Nguyen BN; Nguyen L; Mital S; Bugden S; Nguyen HV
    Diabetes Obes Metab; 2023 Jun; 25(6):1614-1623. PubMed ID: 36751968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.